Skip to main content
. 2020 Apr 29;10:7199. doi: 10.1038/s41598-020-64032-1

Figure 5.

Figure 5

(S)-(+)-carvone (4) does not affect cell viability (a) and decreases IL-1β-induced NOS2 protein levels (b) and NO production (c) as well as pro-IL-1β protein levels (d) in human chondrocytes. The cells were treated with 10 ng/mL IL-1β for 24 h (a, b, c and d), following pre-treatment for 1 h with 666 or 1331 µM of (S)-(+)-carvone (4). As a positive control, the cells were similarly treated with 5 μM Bay 11-7082 (b and c). Control cells (Ctrl) were treated with the vehicle (0.1% DMSO) in the absence of IL-1β. Each column represents the mean ± SEM of, at least, three independent experiments. The blots shown are representative of, at least, three independent experiments and are cropped for clarity and conciseness. The blots shown in Fig. 5b were vertically sliced before the last condition (Bay 11-7082) to exclude a condition not relevant for the present study. The corresponding full-length blots are presented in Fig. S3. ***p < 0.001 and ****p < 0.0001 relative to IL-1β-treated cells. ##p < 0.01, ###p < 0.001 and ####p < 0.0001 relative to the Ctrl. §§§p < 0.001 and §§§§p < 0.0001 between the conditions indicated.